Regulatory hurdles for CAR T-cell therapy in Japan

Lancet Haematol. 2021 Oct;8(10):e686-e687. doi: 10.1016/S2352-3026(21)00279-9.

Author

Sumimasa Nagai¹

Affiliation

¹ Department of Medical Development, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan. Electronic address: sunagai@kuhp.kyoto-u.ac.jp.

PMID: 34560011
DOI: 10.1016/S2352-3026(21)00279-9

No abstract available

MeSH terms

Clinical Trials as Topic
Humans
Immunotherapy, Adoptive* / economics
Immunotherapy, Adoptive* / legislation & jurisprudence
Immunotherapy, Adoptive* / methods
Japan / epidemiology
Lymphoma, B-Cell / epidemiology
Lymphoma, B-Cell / therapy
Marketing
Receptors, Chimeric Antigen / therapeutic use
Treatment Outcome

Substances

Receptors, Chimeric Antigen